A precision-pathogen-testing startup a day keeps the FOMO away
Startup of the Year | Powered by ESTABLISHED

Startup of the Year: Daily Dealflow 

Startup of the Year discovers and supports the
most promising and innovative startups from around the world.
 
Daily Dealflow newsletter delivers one seed-stage startup a day, every work day.
Aperiomics

Aperiomics

Helping chronically sick patients finally get answers, Aperiomics is the ONLY company able to identify EVERY known bacteria, virus, parasite and fungus!
Aperiomics is the only company identifying every known bacteria, DNA virus, fungi and parasite.  Clinicians and patients call on Aperiomics to help identify infections that other tests cannot. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test via deep metagenomic shotgun sequencing of DNA from any sample, be it patient, environmental, or otherwise.  This complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- a comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough, only possible through Aperiomics, can be used to accurately identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about our successes in helping others.  Aperiomics is supported by the National Science Foundation. It was named Life Sciences Innovator of the Year in 2016 and Startup of the Year in 2018.
 
Twitter
Facebook
LinkedIn
Instagram

📍 Location

Ashburn, VA

⚙️ Product Stage

First full release

🏭 Industries

Health & Wellness, Medical 

🤑 Fundraising Status

Actively raising

📈 Last Funding Stage

Seed

💸 Total Funding to Date

undisclosed

Big Wins

This has been an exciting period of recognition and growth for Aperiomics.  Established (founders of media company Tech.Co) has named Aperiomics the 2018 Startup of the Year for its innovation and the important work Aperiomics does to help people suffering from chronic infection.  Earlier this month Icenhour won a $20,000 prize by The Vinetta Project,  a NYC-born collective that aims to close the gender-based VC funding gap by connecting female founders and investors.  In September, Aperiomics announced that the National Science Foundation awarded it an additional $229,000. Over the past two years, Aperiomics has received more than $1.6 million from the NSF. In 2017, the company closed a seed round of funding, raising $512,000 that was led by Pipeline Angels, a national network of new and seasoned women angel investors.  The company was named “Life Sciences Innovator of the Year” in 2016. 
 

Despite extremely limited sales/marketing resources to date, Aperiomics has secured 350+ customers, helped ~ 950+ patients, and generated $1.5M+ revenues since January 1, 2017.  We are FIRST to market and seek to maintain this leader position. The sequencing market is moving fast, necessitating aggressive sales & marketing to ensure market penetration. Due to the specialized and highly technical nature of Aperiomics service, sales and marketing will be handled through direct sales. Peer-reviewed publications, case studies, conference presentations, social media, inbound marketing, and trade shows will be the primary methods for marketing.

Contact the Founder

Crystal Icenhour

[email protected]

ESTABLISHED
Startup of the Year is powered by Established, a consultancy focused on helping organizations with their innovation, startup, and communication strategies.
 
Created by the talent responsible for building the Tech.Co brand (acquired by an international publishing company), we're leveraging decades of experience to help our collaborators further (or create) their brand & accomplish their most important goals.
Facebook Twitter Instagram LinkedIn
Submit your startup
Established, LLC is not a broker-dealer and cannot provide assurances and makes no representations or warranties as to the timing or price terms for any purchase or sale of early-stage company equity. Nothing contained in this email constitutes investment, legal, tax or other advice. No information or statements contained in this email should be relied upon in making an investment or different decision. You should review all risks and consult all applicable professionals when making any investment decisions. Information and statements contained within this email and any attachments are solely for informational purposes and does not constitute an offer to sell or a solicitation to buy any securities.

[Sender_Name]

[Sender_Address], [Sender_City], [Sender_State] [Sender_Zip]

Unsubscribe - Unsubscribe Preferences